TrialClinical cancer research : an official journal of the American Association for Cancer Research2025

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Melanie Royce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.